Inclusion complexes of 5-flucytosine with β-cyclodextrin and hydroxypropyl-β-cyclodextrin: Characterization in aqueous solution and in solid state

Journal of Inclusion Phenomena and Macrocyclic Chemistry

Volumn 62, Issue 1-2, 2008, Pages 117-125

  Spulber, Mariana ^a   Pinteala, Mariana ^a   Fifere, Adrian ^a   Harabagiu, Valeria ^a   Simionescu, Bogdan C ^a  

^a PETRU PONI INSTITUTE OF MACROMOLECULAR CHEMISTRY   (Romania)

Author keywords

5 FC; Cyclodextrin; Inclusion complex

Indexed keywords

EID: 51649130660     PISSN: 09230750     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10847-008-9446-0     Document Type: Article

References (16)

1. Vermes, A., Guchelaar, A.J., Dankert, J.: Flucytosine: a review of its pharmacology, clinical indications, pharmacokinetics, toxicity and drug interactions. J. Antimicrob. Chemother. 46, 171-179 (2000)
2. Hedges, A.R.: Industrial applications of cyclodextrins. Chem. Rev. 98, 2035-2044 (1998)
3. Loftsson, T., Brewster, M.E.: Pharmaceutical applications of cyclodextrins. 1. Drug solubilization and stabilization. J. Pharm. Sci. 85, 1017-1025 (1996)
4. Spulber, M., Pinteala, M., Harabagiu, V., Simionescu, B.C. Inclusion complexes of Sulconazole with β-cyclodextrin and hydroxypropyl β-cyclodextrin: characterization in aqueous solution and in solid state. J. Incl. Phenom. Macro. doi: 10.1007/s10847-007-9391-3
5. Scholer, H.J.: Flucytosine. In: Speller, D.C.E. (ed.) Antifungal Chemotherapy, pp. 35-106. Wiley & Sons, Chichester (1977)
6. Francis, P., Walsh, T.J.: Evolving role of flucytosine in immunocompromised patients: new insights into safety, pharmacokinetics, and antifungal therapy. Clin. Infect. Dis. 15, 1003-1018 (1992)
7. Viviani, M.A.: Flucytosine-what is its future? J. Antimicrob. Chemother. 35, 241-244 (1995)
8. Higuchi, T., Connors, K.A.: Phase-solubility techniques. Adv. Anal. Chem. Instr. 4, 117-212 (1965)
9. Manca, M.L., Zaru, M., Ennas, G., Valenti, D., Sinico, C., Loy, G., Fadda, A.M.: Diclofenac-β-cyclodextrin binary systems: physicochemical characterization and in vitro dissolution and diffusion studies. AAPS PharmSciTech. 6(3), 464-472 (2005)
10. Chala, R., Ahuja, A., Ali, J., Khar, R.K.: Cyclodextrins in drug delivery: un updated review. AAPS PharmSciTech. 6(2), 329-357 (2005)
11. Mukne, A.P., Nagarsenker, M.S.: Triamterene-β-cyclodextrin systems: preparation, characterization and in vivo evaluation. AAPS PharmSciTech. 5(1), 83-90 (2004)
12. Piel, G., Dive, G., Ervard, B., Van Hees, T., Henry de Hassonville, S., Delattre, L.: Molecular modeling study of β- and γ-cyclodextrin complexes with miconazole. Eur. J. Pharm. Sci. 13, 271-279 (2001)
13. Wang, P., Jeng, R.: Separation of purine and pyrimidine bases by capillary electrophoresis using β-cyclodextrin as an additive. J. Pharm. Biomed. Anal. 9(6), 277-283 (2004)
14. Vrkic, A., O'Hair, R.A.J.: Unusual covalent bond-breaking reactions of β-cyclodextrin inclusion complexes of nucleobases/nucleosides and related guest molecules. Eur. J. Mass. Spectrom. 9(6), 563-577 (2003)
15. Figueiras, A., Ribeiro, L., Vieira, M.T., Veiga, E.F.: Preparation and physicochemical characterization of omeprazole: methyl-beta-cyclodextrin inclusion complex in solid state. J Incl Phenom Macrocycl Chem. 57, 173-177 (2007)
16. Moyano, J.R., Gine's, J.M., Arias, M.J., Rabasco, A.M.: Study of the dissolution characteristics of oxazepam via complexation with β-cyclodextrin. Int. J. Pharm. 114, 95-102 (1995)